Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20729579 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200722 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL26893965 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL91558 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL8304417 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL27043970 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL200978 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL72827 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL13216436 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 | |
| SCHEMBL2965236 | 0.91 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3EPHX1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116063215-A | Synthesis method of 4-amino-L-proline | 南京安淮创新药物研究院有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115010638-B | Synthesis method of Nemactetvir intermediate | 杭州国瑞生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2023216317-A1 | METHOD FOR SYNTHESIZING NIRMATRELVIR INTERMEDIATE | 杭州国瑞生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| CN-116063215-A | Synthesis method of 4-amino-L-proline | 南京安淮创新药物研究院有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-116063215-A | Synthesis method of 4-amino-L-proline | 南京安淮创新药物研究院有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115010638-A | Synthesis method of nemadevir intermediate | 杭州国瑞生物科技有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20160002159-A1 | PERFLUORO-TERT-BUTYL HYDROXYPROLINE | ZONDLO NEAL (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8674088-B2 | Antiviral phosphinate compounds | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8637449-B2 | Processes for preparing protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-0731696-A4 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK INC (US) | 1999-04-21 | — | — | EP | disclosed |
| US-5849893-A | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics | BAYER AKTIENGESELLSCHAFT (DE) | 1998-12-15 | — | — | US | disclosed |
| US-5663380-A | ANTIARTHRITIC AGENTS; TREATMENT OF RHEUMATOID ARTHRITIS | PROTOTEK, INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0731696-A1 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK, INC. (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5486623-A | Cysteine protease inhibitors containing heterocyclic leaving groups | PROTOTEK, INC. (US) | 1996-01-23 | — | — | US | disclosed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | disclosed |
| WO-1995015749-A1 | CYSTEINE PROTEASE INHIBITORS CONTAINING HETEROCYCLIC LEAVING GROUPS | PROTOTEK, INC. (US) | 1995-06-15 | — | — | WO | disclosed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| US-5374720-A | A thienamycins bactericides has nontoxic, side effect reduction against the kidney and central nervous system | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002159-A1 | PERFLUORO-TERT-BUTYL HYDROXYPROLINE | FIBP, HDGF, PLOD3 | CHRM2 4268/4885CHRM1 3948/4885CHRM3 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.